The role of genius is not to complicate the simple, but to simplify the complicated.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With amarin aug 2013 - sept 2021
"Dr Nissen is adamant that R-IT was a false positive trial … ie we saw harm from the placebo used rather then benefit from the drug ( Vascepa ) "
One woukd think, if the trial participates were harmed by consuming 4g of mineral oil ... Daily ... For years ... There would be a class action lawsuit.
"had a charge of $9.6 million related to unsellable inventory not related to product dating."
Packaging problem, insert problem, capsule labelling problem?
Packaged product damaged during shipping or in storage?
Couldn't be an api or capsule problem, could it?
QA would have caught those problems.
"we were able to retain a level of market share even to this day that is unprecedented in any generic market,"
A worthwhile soundbyte there
How about those offsetting loss carry forwards?
I could see, buy up to $x worth under $1.70, and 55,000 was all he could get.
No idea.
Just odd for someone worth 8,9,10 digits
To buy $93,000 worth of a stock.
55,000 shares at $1.686 avg.
Strikes me odd, someone of his wealth would allocate such an amount.
I mean, what did he say to the broker, how ever many shares in can get for $93,000?
Anyone here using blinkRx to fill their vascepa prescription?
We certain both trades occurred between two or more parties, all of whom either bought or sold.
another one ... a ... pattern emerges
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168668831
808,300 print at 15:00:07
On level2, it's odd how many bid/ask changes are taking place with very few order executions.
Or patent application, or shared rights agreement negotiation between KP and amarin
If we're speculating ... How about results so unexpectedly positive they've decided an independent confirmation of the data analysis is mandatory.
so EDDING gets to market the Reduce-IT indication in china without further negotiations with amarin? the original agreement preceded the successful results of the reduce-it trial.
https://investor.amarincorp.com/news-releases/news-release-details/amarin-and-eddingpharm-announce-agreement-develop-and
Late this year (are they hoping for something to occur at end of February?)
2022
Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022
2021
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021
2020
Amarin To Report Fourth Quarter and Full Year 2019 Results and Host Conference Call on February 25, 2020
2019
Amarin To Report Fourth Quarter and Full Year 2018 Results and Host Conference Call on February 27, 2019
2018
Amarin to Report Fourth Quarter and Full Year 2017 Results and Host Conference Call on February 27th, 2018
clairvoyance or time travel.
other than, "who are the members of epadi?"
i can't think of anything asked that wasn't covered in the briefing.
anyone hear something?
timeliness of filing, covered
derivative case, covered
fraud/mistake, covered
remedy, covered
Were the judges' names just announced, or something?
now 11.7M shares in the same 20 cent range, 3.41.-3.62.
ridiculous!
i see ~8.6M shares traded between 3.41-3.62.
GSCO bid 9,700 3.48, GSCO ask 9,700 3.68
any time the current bid or the current ask challenges theirs,
they scurry away from the action.
Ridiculous number of shares trading in a small range while the market is aware the stock is under accumulation.
What is with MM GSCO always at 9700 ask, always jumping away from the sale?
Mere speculation on my part, but perhaps we have a (or some) "buy everything below $n.nn" order(s) in play
Excellent to see so many 4/5 digit trades.
Real interest!
Who the hell is selling while it's now obvious sarrisa has a vacuum cleaner for amrn shares?
Could be seeing more of these daily since they now exceed 5% ownership.
fascinating, thanks!
i would sure like to review some jury instructions in relevant cases.
wouldn't even know where to look though.
no, i don't think so.
i am saying, it appears on the surface to be simple to get a jury to agree that lesser cost to a consumer is an inducement to select one product over another.
a jury trial...
dear jurists,
if you as a consumer of a product were given the option to (co)pay less for equivalent products, would you chose the greater or lesser cost product?
by show of hands, the greater cost product anyone? anyone?
Material event, yes? Where's the sec filing/PR?
Dont believe you possess adequate understanding of 3rd party payor rights to offer more than unsupported speculation. A patient can always obtain access to vascepa via self funding.
"Looking through my rose-colored investor's glasses, the ruling can be cheered by Amarin and waved in the face of every insurance company and pharmacy that tries to use formulary selection and the prior authorization process to screw Amarin out of Vascepa sales. "
could also lead to both branded and generic icosapent ethyl being entirely removed from formularies. No coverage for either branded or generic would also lead to no infringement.
When we lose hikma (the manufacturer of ALL generic vascepa rx) we lose alot of treble damages when compared to healthnet, an insurer of some covered patients with generic vascepa Rx.
(Merck, through a subsidiary, will acquire Acceleron for $180 per share)
https://www.sec.gov/Archives/edgar/data/0001331852/000110465921142280/xslF345X03/tm2133601-13_4seq1.xml
com'on joe, you can afford to do much better than 12k of AMRN
($7.4M before taxes from acceleron buyout)
https://www.sec.gov/edgar/browse/?CIK=0001331852